Table 1.
Characteristics of participants (n=211)
| Characteristics | Mean (SD) or n (%) |
|---|---|
| Age, yr | 72.3 (9.0) |
| Female sex | 118 (56%) |
| Black race | 46 (22%) |
| Education, yr | 7.8 (2.4) |
| Body mass index, kg/m2 | 29.6 (5.5) |
| History of CVD | 24 (11%) |
| Systolic BP, mm Hg | 139.8 (17.4) |
| Diastolic BP, mm Hg | 75.2 (12.4) |
| Use of Angiotensin II receptor blockers | 57 (27%) |
| Use of ACE inhibitors | 74 (35%) |
| eGFR, ml/min per 1.73 m2 | 45.9 (10.4) |
| Scanner | |
| 3T GE MR750W | 14 (7%) |
| 3T Philips Achieva 3.2 | 69 (33%) |
| 3T Siemens Skyra VD11B | 19 (9%) |
| 3T Siemens Tim Trio VB17 | 45 (21%) |
| 3T Siemens Verio VB17 | 64 (30%) |
| Outcomes, mean (SD) | |
| Total brain volume, cm3 | 1110.6 (115.3) |
| Total brain CBF, mL/100 mg/min | 38.3 (12.3) |
| Abnormal WML volume, cm3 | 2.3 (1.0) |
| Urine biomarkers, median (IQR) | |
| IL18, pg/ml | 30.6 (16.4, 57.1) |
| KIM-1, pg/ml | 848.0 (388.2, 1596.3) |
| NGAL, ng/ml | 27.6 (14.7, 59.2) |
| YKL40, pg/ml | 9.10 (7.7, 10.3) |
| MCP-1, pg/ml | 180.7 (89.6, 329.1) |
| A1M, mg/g | 13.4 (7.1, 24.95) |
| B2M, ng/mL | 104.2 (38.8, 333.5) |
| Umod, ng/ml | 6.5 (4.3, 9.9) |
| Urine albumin, mg/g | 17 (8, 52) |
CVD, cardiovascular disease; CBF, cerebral blood flow; WML, white matter lesions; IQR, interquartile range; IL-18, interleukin-18;KIM-1, kidney injury molecule-1; NGAL, neutrophil gelatinase-associated lipocalin; YKL40, chitinase-3-like protein; MCP-1, monocyte chemoattractant protein-1; B2M, β2-microglobulin; A1M, α1-microglobulin; Umod, uromodulin.